

## Supplemental Tables and Figures

Table S1. Transcript specific primers used for transcript accumulation analyses (sqRT-PCR and qRT-PCR) throughout this study.

Reference Number	Target	Direction	Primer Sequence (5' → 3')
AJ236020	<i>PhI8S</i>	Forward	TTAGCAGGCTGAGGTCTCGT
		Reverse	AGCGGATGTTGCTTTTAGGA
JQ031717	<i>PhAAE</i>	Forward	GTACAGTCACAGAGGAGC
		Reverse	CGGGAGTCGTTATTTCCG
JQ031717	<i>PhAAE</i>	Forward	ATGGTGCCCAAAGCATGT
		Reverse	GAGCTGGCAATCAAGGAATC
L10115	<i>PhFBP1</i>	Forward	TGCGCCAACTTGAGATAGCA
		Reverse	TGCTGAAACACTTCGCCAATT
EU751616	<i>PhCM1</i>	Forward	CCCTGATGAGCACCATTTC
		Reverse	ACTGCATGGGTGGCAACAC
AY705976	<i>PhPAL1</i>	Forward	GCTAGGCGGTGAGACGCTAA
		Reverse	CTCGGACAGCTGCACTGTCA
CO805160	<i>PhPAL2</i>	Forward	ACTGGCAGGCCTAATTCCAA
		Reverse	GCGAAACGCTTCTTCAGCAT
AY611496	<i>PhBPBT</i>	Forward	AGTGATGCACCCGGTCTTGT
		Reverse	CAATTCTCGGCACCACACTG
AY233465/ AY233466	<i>PhBSMT</i>	Forward	TTTTTCAGTGGAGTGCCTGGTT
		Reverse	GGCACCTGAGATAGCCACATG
HM447144	<i>PhC4H1</i>	Forward	AGCAGGTGTAACAAACTGCAA
		Reverse	AAACTGGGACAGGGATAGGA
HM447145	<i>PhC4H2</i>	Forward	AACTTGTCCAAACA AAAATGGA
		Reverse	TGGCAATTTAAAACGTTTGCT
AY705977	<i>PhIGS1</i>	Forward	GCCTATGTCATGCCATTGAA
		Reverse	TGCTTTAATTGTGTAGGCTGC
HM447143	<i>PhMYB4</i>	Forward	AACAATTTCTTTTGCTGCTGGAA
		Reverse	TTCATCGTCCTTGATTTGTCAA
DQ243784	<i>PhPAAS</i>	Forward	TCCTTGTAGTTCTAGTACTGCTGGAA
		Reverse	TCAACAGCAGTTGTTGAAGTAGTTC
DQ767969	<i>PhCFAT</i>	Forward	AGGCAACTCGCAATGGAAGT
		Reverse	AGGCGCTGAAACACTCCAAT
FJ657663	<i>PhKAT1</i>	Forward	GCCCCACCATTACATTAAC
		Reverse	GCCCCACCATTACATTAAC
AY705977	<i>PhODO1</i>	Forward	TGCTTCAACCATGTCGAATTG
		Reverse	TCCGTGCCTGTTCTCTACGTT

Figure S1. A schematic of the *PhAAE* cloning strategy. SMART-RACE cloning kit (Clontech, Mountain View, CA) was used according to the manufacturer's specifications. In brief: a 5' cDNA library (universal adapter linked to the guanine cap, UA) and a 3' cDNA library (universal adapter linked to the poly-adenylated tail, UA) were generated from total RNA isolated from MD petal tissue. *PhAAE* specific primers (GSP-F and GSP-R) were designed from the EST sequence information available for *PhAAE*. The 'north' section of the *PhAAE* transcript was amplified and cloned out of the 5' library, and the 'south' section was amplified and cloned out of the 3' library. From these sections primers were designed outside of the coding sequence (CDS) and the entire *PhAAE* CDS was amplified and cloned into a pGEM®-T Easy vector (Promega, Madison, WI) from a general cDNA population produced from MD petal tissue. The CDS construct was sequenced extensively (UF ICBR sequencing core, Gainesville, FL).

Figure S2. A comparative *PhAAE* transcript accumulation analysis with MD and 44568 (sqRT-PCR). Floral developmental analysis used MD and ethylene-insensitive 44568 flowers from 11 sequential stages collected on one day at 16:00 h (A). Ethylene treatment (two  $\mu\text{L L}^{-1}$ ) analysis used excised MD (B) and 44568 (C) whole flowers treated for 0, 1, 2, 4, and 8 h. Total RNA was isolated, purified, and quantified. 50 ng of total RNA for each sample was used for sqRT-PCR reactions. Transcript specific primers for *PhAAE* were used with 27 cycles of amplification. *Ph18S* was used as a loading control with 18 cycles of amplification.


Figure S3. *PhAAE* recombinant protein expression in *E. coli* BL21/(DE3) cells. A 10% SDS-PAGE gel image of proteins from a standard protein ladder (1), cell fractions representing a non-induced culture harboring pET32-*PhAAE* (2), an induced (1 mM IPTG at 37°C for 18 H) culture harboring pET32-*PhAAE* (3), soluble fraction of the induced culture (4), insoluble pellet fraction from induced culture (5), and soluble fraction after inclusion body isolation and His-Bind® resin purification (6). Prediction models estimate the TRX-*PhAAE* fusion protein to be approximately 78 kilo Daltons (KDa).

Figure S4. Schematic representation of the full-length *PhAAE* transcript model as shown in Vector NTI Advance™ 11. Depicted are the 5' and 3' untranslated regions (UTR), the coding sequence (CDS), the RNAi induction sequence region used for generating the *ir-PhAAE* plants, the highly conserved AMP-binding site (IPR020845), and the AMP-dependent synthase/ligase domain (IPR000873).

Figure S5. Comparative sqRT-PCR transcript accumulation analysis. MD and *ir-PhAAE* T<sub>0</sub> flowers were developmentally staged and collected at 16:00 H, total RNA was isolated, purified, and quantified. 50 ng of total RNA for each sample was used for sqRT-PCR reactions. Transcript specific primers for *PhAAE* were used with 24 cycles of amplification. *Ph18S* was used as a loading control with 15 cycles of amplification. All *ir-PhAAE* T<sub>0</sub> individuals are a result of an independent transformation event.

Figure S6. FVBP emission analysis of representative plants from MD, *ir-PhMYB4*, *ir-PhAAE*, and resulting progeny from crossing *ir-PhMYB4* and *ir-PhAAE*. Developmentally staged flowers (stage 8) were used to collect FVBP emission at 18:00 h (mean ± se; n = 3). Four major FVBP compounds were identified and quantified with all measurements ng/g fresh weight/hour. Figure S1.

PhAAE (JQ031717): 1997 bp



Full Length CDS



```

1      COGGGCTTCT GCGGGTTGAG GGGCTTCCAG TCTTAACAA CCACTATAGG CAATTTCTT GTATACAAAT COGGGGTCTG TGTACATCT TCAGTGAGCC ATCATCCTAT CCTCTTTC
121    TCTCTCCAC CAAAATGGCT CTGACAGCCA CAGCCACCAC CAGAGGTGGC TCAGCCCTCC CAAATTCATG CCTTCAAACC CCAAAGTTTC AATCTTTACA AAAJCCCACC TTCATTTTCT
141    F P T N K I T K P R T K H I S A V Q S P P S T T K W N L E S W K T K P A F Q L P
241    CCTTCCCAC CAACAAAAA ACCAAGCCA GAACCAACA CATCTCAGCC GTTCAATCAC CACCTTCAAC AACAAAAATG AATCTTGA A GTTGAAAAAC AAAJCCAGCT TTCAACTAC
261    D Y P D K Y E L E S V L K T L S T Y P P I V F A G E A R N L E E K L G E A A L G
361    CTGATTACC TGATAAAGT GAGCTGGAAT CTGTTCTGAA GACCCCTTCA ACTTATCCAC CAATTTGATT TGCTGGGGAA GCAAGGAATC TTGAAGAA A ATTAGTGAA GCTGCTCTG
381    N A F L L Q G G D C A E S F K E F S A N N I R D T F R V M L Q M G V V L M F G G
481    GAAATGCTT TTTATTGCA GGTGGTATT GTGCTGAG TTTTAAAGAG TTTAGTCTA ATAATATTAG AGATACTTTT AGAGTTATG TGACAGATGG TGTGTTCTT ATGTTTGTTG
501    Q M P V I X V G R M A G Q F A K P R S D P F E E K D G V K L P S Y R G D N V N G
601    CTCAAATGCC TGTATCAAG GTGGGTAGAA TGGCAAGTCA ATTTGCCAAG CCAAGATCTG ATCCATTGA AGAGAAGGAT GCGGTGAAG TACCAAGTTA CAGGGAGAC AATGTGAATG
621    D A F D E I S R I P D P H R M V R A Y T Q S V A T L N L L R A F A S G G Y A A M
721    CTGATGCTT TGACGAGAA TCAAGAATC CTGACCCCA TAGGATGOTG AGGCTATA CTGAATCTGT AGCTACGCTG AACCTCTCA GGCATTTC TAGTGGAGT TATGCTCCA
741    Q R V H Q Y H L D F T D Q S E Q G D R Y R E L A E R V D E A H G F H T A G L T
841    TCGAGAGGT TACCMSTG ANTCTGACT TCACTGATCA GAGCGAGCAA GGTGACAGT ACCGTGACT GCTCACCGA GTTGACGAG CCATGGGCTT CATGCTCT GCTGGGCTTA
861    V D H T I H T T T D F W T S H E C L L L P Y E Q A L T R E D S T S G L Y D C S
961    CAGTTGACCA CACATCAG ACTACAAG ACTTCTGAC ATCTCATGAG TGCTTCTCT TGCTTATGA ACAAGCACT ACAAGGAGG ATTCAGCTT TGCTGTAT TATGACTCT
981    A H M I W Y G E R T R Q L D G A H V E F L R G I A N P L G I K V S H K M D P D E
1081  CTGCTCATAT GATTTGGGT GGGGAACGA CAAGCAATT GGATGOTGCT CAGTTGAGT TCTGAGAGG AATTGCCAAT CCACTTGTG TCAAGGTGAG CCACAAAATG GATCCAGATG
1101  L V K L I D I L N P Q N K P G R I T V I T R H G A D N M R V K L P H L I R A V R
1201  AACTAGTCAA GCTTATTGAC ATTTAAACC CTCAAAATA ACCAGGAGA ATACAGTGA TCACCAGAT GGGAGCTGAC AACATGAGAG TAAAGCTTC CCACTGATC AGGCTGTCC
1221  G A G Q I Y T W V S D P M H G N T T K A P C G L K T R S F D S I R A E L R A F F
1321  GTGGAGCGG TCAAATTGC ACTTGGGTTA GTGATCTAT GCATGGGAAT ACCTAAAG CCGCTTGGG ACTCAAACCT CGTTCAITG ATTCTATCAG GCGTGAGCTA AGAGCTTCT
1341  D V H E Q I G S Y P G G V H L E M T G Q N V T E C V G G S R T I T Y N D L S S R
1441  TTGATGTACA TGAACAAGAA GGGAGCTATC CTGGTGGGT GCATCTGGAG ATACAGGTC AGAATGAAC AGAGTGGCTT GGAGGGTCTC GAACAATTAC TTACAAGAT CTGAGCTCGC
1461  Y H T H C D P R L N A S Q A L E L A F A I A E R L R R R R L G P K F S L
1561  CTTACCATAC ACATTGTGAC CTTAGACTGA ATGCTTCTCA AGCATTGAA CTGCTTTG CTATCGCGA ACGACTTAG AGAAGAGAC TAGGACCGAA GTTCAGTCTC TAGAATGCT
1581  CTGCTACCC TTCCCCTAT TTAGGCTGTG AGTGTGTGTA TGAAGTATA AGAGTAGTAT GCCAAGATCT AATAATAGTA AAGCATGAG AGCTTAAAG TCACTCAGTT GTGACAAAG
1601  TGTTAATATA TGTTAAGAG ACCTTTGTGT GTGTATATAT TAGCATATGT AAGATAACTT CTTTCAAGT GTAGTGAGT AOTCTTTAG GTTTAAAGAA AAAAATAA AAAACCGCA
1621  CTAGAT
    
```

Figure S2.




Figure S3.




Figure S4.




Figure S5.






Figure S6.

